News Article | February 28, 2017
MastersinAccounting.info, a leading career and education website focused on graduate programs in accounting and finance, has released its ranking of the Top Online Master’s in Accounting Programs. To be considered for the list, schools with an online master’s in accounting program were checked for not-for-profit status and accreditation from one of the six regional accreditation agencies in the US recognized by the US Department of Education. The online degrees from the schools on the list are also the same degrees granted to traditional, on-campus students. The rankings were based on factors measuring academic quality, student experience, and graduate success. The ranking uses a unique methodology that considers such factors as the average tuition cost per online credit hour; program accreditation by the AACSB, ACBSP, or IACBE; the average mid-career pay of alumni; and school rankings according to US News & World Report in the regional, national, and online categories. Rob Voce, founder of MastersinAccounting.info, said about the list: “Enrollment in online degree programs is increasing and schools are responding by offering more distance education programs at the graduate level - which can be particularly convenient for those who are already working full-time. Our ranking is designed to help these prospective students learn about and compare first-rate online master’s in accounting programs that offer long-term value.” Overall, 37 schools with online master’s in accounting programs satisfied the inclusion requirements and ranked on this list. Auburn University, in Auburn, Alabama, captured the top spot on the list, followed by the University of North Carolina at Chapel Hill in the second spot. As well as providing schools’ results on ranking factors, the Top Online Master’s in Accounting Programs list includes detailed information on schools’ admissions statistics and requirements as well as tuition comparisons. For the top-ranking schools the list also provides: The top schools on this year’s list are: 1. Auburn University Raymond J. Harbert College of Business (Auburn, AL) 2. University of North Carolina Kenan-Flagler Business School (Chapel Hill, NC) 3. University of Connecticut School of Business (Storrs, CT) 4. University of Massachusetts Amherst Isenberg School of Management (Amherst, MA) 5. Pennsylvania State University World Campus (State College, PA) 6. University of Southern California Marshall School of Business (Los Angeles, CA) 7. Emporia State University School of Business (Emporia, KS) 8. Rutgers, The State University of New Jersey Business School (New Brunswick, NJ) 9. Colorado State University College of Business (Fort Collins, CO) 10. University of Alabama at Birmingham Collat School of Business (Birmingham, AL) 11. University of Texas at Dallas Naveen Jindal School of Business (Richardson, TX) 12. St. John’s University Peter J. Tobin College of Business (Jamaica, NY) 13. Georgia Southern University College of Business Administration (Statesboro, GA) 14. Northeastern University D’Amore-McKim School of Business (Boston, MA) 15. DePaul University Kellstadt Graduate School of Business (Chicago, IL) 16. Golden Gate University Edward S. Ageno School of Business (San Francisco, CA) 17. Southern New Hampshire University College of Online and Continuing Education (Hooksett, NH) 18. California State University, Sacramento College of Business Administration (Sacramento, CA) 19. University of Scranton Kania School of Management (Scranton, PA) 20. Syracuse University Martin J. Whitman School of Management (Syracuse, NY) 21. University of Hartford Barney School of Business (West Hartford, CT) 22. University of Miami School of Business Administration (Coral Gables, FL) 23. George Mason University School of Business (Fairfax, VA) 24. University of South Dakota Beacom School of Business (Vermillion, SD) 25. Florida Atlantic University College of Business (Boca Raton, FL) 26. Stetson University M.E. Rinker Sr. Institute of Tax and Accountancy (DeLand, FL) 27. Rider University College of Business Administration (Lawrenceville, NJ) 28. New England College School of Graduate and Professional Studies (Henniker, NH) 29. Western Governors University (Salt Lake City, UT) 30. Indiana Wesleyan University DeVoe School of Business (Marion, IN) 31. Plymouth State University College of Business Administration (Plymouth, NH) 32. Bellevue University College of Business (Bellevue, NE) 33. Loyola University Chicago Quinlan School of Business (Chicago, IL) 34. Franklin University Ross College of Business (Columbus, OH) 35. Nova Southeastern University Huizenga College of Business (Fort Lauderdale, FL) 36. Saint Mary’s University Graduate School of Business and Technology (Winona, MN) 37. Baypath University School of Science & Management (Longmeadow, MA) *See the full rankings and program details here: http://www.mastersinaccounting.info/online-masters-in-accounting/ About MastersinAccounting.info: MastersinAccounting.info is a free online resource focused on providing accurate and up-to-date information on degrees, programs, and schools for prospective master’s in accounting students. The site also provides additional resources such as career outlooks, graduate student guides, scholarships, and more. MastersinAccounting.info’s goal is to be best in class.
News Article | February 23, 2017
CLEVELAND, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today a presentation featuring its MultiStem® cell therapy treatment for ischemic stroke at the International Stroke Conference 2017 this week in Houston. Dr. Kiyohiro Houkin, Professor and Chairman at Department of Neurosurgery of Hokkaido University Graduate School of Medicine, and Director of Hokkaido University Hospital, will present an overview of the Treatment Evaluation of Acute Stroke Using Regenerative Cell Elements (TREASURE) study, which is the Phase II/III trial of MultiStem (HLCM051) being conducted by HEALIOS K.K. in Japan. Athersys and Healios entered into a license agreement in January 2016 and have been collaborating on the development and commercialization of MultiStem for the treatment of stroke in Japan. Athersys completed a Phase II clinical study (MASTERS-1) of its proprietary MultiStem cell therapy for the treatment of ischemic stroke and is currently preparing for a registrational Phase III study that will be conducted in the U.S., Europe and Canada. Dr. Houkin’s presentation entitled, Treatment Evaluation of Acute Stroke Using Regenerative Cell Elements (TREASURE): A Randomized Controlled Phase II/III Trial of MultiStem (HLCM051), will take place during the session beginning at 6:15 PM CST today at the George R. Brown Convention Center, Hall E. “We are very excited to be commencing this clinical trial at Hokkaido University Hospital and then at other leading stroke centers across Japan,” said Dr. Houkin. “The need for safe, effective and clinically-practical treatments for ischemic stroke patients has never been greater. Based on the clinical results from the recently completed MASTERS-1 Phase II clinical study, many believe that innovative treatments like MultiStem cell therapy hold great promise for treating the devastating effects of a stroke and helping patients recover more effectively. Given the rapidly expanding aging population both in Japan and globally, safe and effective treatments that can reach a greater number of stroke victims could make a significant difference for many patients and their families.” In conjunction with the ISC 2017 conference, Athersys also announced an informational video featuring former NFL player and stroke survivor Tedy Bruschi. Available for viewing at https://www.youtube.com/user/AllianceRegenMed, the video focuses on the potential of increasing the post-ischemic stroke treatment window while chronicling the challenges facing doctors with today’s limited options. CBS broadcaster Solomon Wilcots moderates the video that includes stories of both Bruschi and a Houston stroke survivor who participated in the MASTERS-1 study. The International Stroke Conference is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease. Clinical Sessions focus on community risk factors; emergency care; acute neuroimaging; acute endovascular and acute nonendovascular treatment; diagnosis of stroke etiology; cerebral large artery disease; in-hospital treatment; clinical rehabilitation and recovery; and health services, quality improvement, and patient-centered outcomes. Basic Science Sessions focus on vascular biology in health and disease; basic and preclinical neuroscience of stroke recovery; and experimental mechanisms and models. Further specialized topics include pediatric stroke; intracerebral hemorrhage; nursing; preventive strategies; vascular cognitive impairment; aneurysms; subarachnoid hemorrhage; neurocritical care; vascular malformations; and ongoing clinical trials. Presentations on these topics attract a wide range of healthcare professionals and investigators including adult and pediatric neurologists; neurosurgeons; neuroradiologists and interventional radiologists; physiatrists; emergency medicine specialists; primary care physicians; hospitalists; nurses and nurse practitioners; rehabilitation specialists; physical, occupational, and speech therapists; pharmacists; and basic researchers spanning the fields of cerebrovascular function and disease. MultiStem cell therapy is a patented regenerative medicine product that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The product represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent safety profile demonstrated in both preclinical and clinical settings, MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need. Athersys has forged strategic partnerships and a broad network of collaborations to develop MultiStem cell therapy for a variety of indications, with an initial focus in the neurological, cardiovascular and inflammatory and immune disorder areas. Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," “suggest,” "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face that could cause actual results to differ materially from those implied by forward-looking statements are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, such as the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem for the treatment of ischemic stroke, acute myocardial infarction, spinal cord injury and acute respiratory distress syndrome and other disease indications, including graft-versus-host disease. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: the success of our collaboration with Healios and others, including our ability to reach milestones and receive milestone payments, and whether any products are successfully developed and sold so that we earn royalty payments; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our collaborators' ability to continue to fulfill their obligations under the terms of our collaboration agreements; the success of our efforts to enter into new strategic partnerships or collaborations and advance our programs; our ability to raise additional capital; results from our MultiStem ongoing and planned clinical trials, including the MASTERS-2 Phase 3 clinical trial and the Healios TREASURE clinical trial in Japan; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials within the expected time frame or at all; changes in external market factors; changes in our industry's overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
News Article | March 3, 2017
SEATTLE--(BUSINESS WIRE)--Impel NeuroPharma, a Seattle-based clinical-stage biotechnology company developing first-in-class intranasal drug treatments, announced today the appointment of Timothy S. Nelson as Independent Director of the Board of Directors. Mr. Nelson has over 20 years of experience with drug delivery, medical devices and drug device combinations. Most recently, Mr. Nelson served as MAP Pharmaceuticals’ President and CEO and as a member of its Board of Directors from April 2005 until March 2013. MAP was acquired by Allergan for $960 million. During that time, Mr. Nelson led the company through its initial public offering and developed LEVADEX, an inhaled dihydroergotamine for migraine. Prior to MAP, he served as Senior Vice President of Commercial and Business Development at DURECT Corporation and has held various senior management positions with Medtronic, including Business Director of the Neurological Division for Europe, the Middle East and Africa, and as Manager of Drug Delivery Ventures. Mr. Nelson has served on several boards, including Chairman of the Board of Civitas, a private biopharmaceutical company focused on treating undermet medical needs in neurological indications from December 2013 to October 2014. The company was acquired by Acorda Therapeutics for $525 million that year. He also served on the Board of Directors of Surmodics, a public medical technology company, from February 2014 to March 2015. Mr. Nelson holds a Master’s degree in Management with distinction from the Kellogg Graduate School of Management at Northwestern University and a Bachelors in Chemical Engineering from the University of Minnesota. “We are very excited to bring Tim onto Impel’s Board of Directors. Tim brings a deep knowledge of both medical devices and pharmaceutical products that will help Impel drive clinical development of our drug-device combination products,” said John Hoekman, Impel’s Founder & CEO. “Impel is developing nasally administered products to treat migraine, Parkinson’s, and Alzheimer’s disease. Tim’s experience and leadership will help Impel advance these therapies through clinical testing and into the hands of patients.” “Impel’s unique, cutting-edge technology has the potential to make a substantial step forward in more effective delivery of drugs which can mean better outcomes for millions of patients who are underserved by existing therapies,” Mr. Nelson said. “I am very pleased to be able to contribute to Impel’s mission and growth.” Impel NeuroPharma’s POD™ nasal drug delivery platform is designed to deliver drugs to the upper nasal cavity for improved biodistribution. By delivering therapeutics to the upper nasal cavity, the POD nasal delivery platform takes advantage of the vascular rich olfactory region for improved bioavailability and has the potential to target the brain via the olfactory and trigeminal nerves. Delivery of therapeutically meaningful levels of drugs may allow for development of more effective drugs and expand the range of treatment options available to patients. Impel NeuroPharma, Inc. is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel NeuroPharma has developed a novel drug delivery platform, the POD™ technology, that administers drug to the deep nasal cavity to improve the biodistribution of many drugs. Impel NeuroPharma’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma please visit our website: http://impelnp.com/. NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Impel NeuroPharma, Inc.’s plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to Impel’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Impel’s undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
News Article | February 19, 2017
FILE - In this Feb. 22, 2106 file photo, a pedestrian walks by the library at the Georgia State University campus in Atlanta. Getting through college is not an easy task, but it can be even harder for low-income or first generation students who have few support resources. Now big data can help them. Researchers at Georgia State University spent four years analyzing students’ grades, test scores and other data in order to identify those who were at risk of failing and promptly assist them. The results have been remarkable: the number of students graduating has jumped by 30 percent and students are spending less time and money to earn a degree. (AP Photo/David Goldman, File) WASHINGTON (AP) — Getting through college isn't easy, and it can be even harder for low-income and first generation students with few support resources. A new tool involving big data can help those at risk. Researchers at Georgia State University spent four years analyzing students' grades, test scores and other information in order to identify those in potential trouble, and promptly assisted them. The study shows the number of students graduating has jumped by 30 percent and that students are spending less time and money to earn a degree. "These are really encouraging gains," said Timothy Renick, the school's vice president for enrollment management and student success and the principal investigator in the study. "Because of these proactive interventions all students benefited, but the students who benefited the most were first generation, low-income and students of color." Renick presented the study at the American Association for the Advancement of Science conference in Boston on Saturday. Inspired by Renick's results, the Education Department awarded a four-year $8.9 million grant that will significantly expand his study. The project, which kicked off last year, will involve 10,000 low-income and first generation students at Georgia State and 10 other large public research universities. While some students are good at keeping track of their academic progress, students from low-income backgrounds may find it more difficult to spot a problem, chose the right courses from an abundance of offerings and navigate the university bureaucracy. That's because they may not have relatives or friends who had gone to college and could offer advice. Gabriella Salinas, a 21-year-old junior at Georgia State majoring in marketing, said she was doing well academically, but then received an F early in her finance class. She successfully completed the course with extra help from her professor. "Not everybody has somebody to turn to and when an academic adviser asks them 'Hey is there anything we can do, what's going on?' They feel as if they have somebody to turn to who actually cares about their success," she said. Renick analyzed past student data at Georgia State to make forecasts about current students' academic outcomes, a type of study known as predictive analytics. For instance, a grade of C in an entry-level class in a student's major was a sign that student would struggle with more advanced courses. Scoring poorly in a math class meant problems for STEM majors. When such warning signs were spotted, academic advisers reached out to students to guide and counsel them. As a result, STEM degrees awarded to black students rose by 69 percent, to black male students by 111 percent and to Hispanics by 226 percent. The average time to a bachelor's degree at Georgia State decreased by more than half a semester, enabling the Class of 2016 to save $15 million in tuitions and fees. "We are leveling the playing field not by doing academic work for the students ... but instead by giving them timely information about what might maximize their chances of graduation," Renick said. "We have a moral obligation to these students and their families many of whom are taking out large loans to give them every chance to graduate." Martin Kurzweil, director of the Educational Transformation Program at Ithaka S+R, a nonprofit research group tasked with evaluating Renick's study because it relies on federal money, called the result "pretty much unprecedented, it's fantastic." He stressed that it was important to keep the data protected lest it be used for commercial purposes or identity theft. Some experts have voiced concern that the large amounts of student data collected could be used for profiling. But Ellen Wagner, a researcher who has studied predictive analytics in education, said it would be hard to help the students without first identifying their problems. "Why would we want to put a metaphorical Band-Aid on a headache?" Wagner said. "If we can remove the guesswork of trying to support students to be the most successful they can be, then we owe them the respect to find where they are strong and where we can help them be stronger and get on with their lives." Ryan Baker, associate professor at University of Pennsylvania's Graduate School of Education, said that similar algorithms have been proved successful in auto insurance and banking. "Any technology can get misused, but I tend to think that for students at risk, prediction systems are doing more good than harm," Baker said.
News Article | February 15, 2017
WORCESTER, MA - A father's nicotine use may have a significant impact on children's risk of some diseases. In a study published in the online biomedical sciences journal eLife, Oliver J. Rando, MD, PhD, and colleagues at UMass Medical School, demonstrate that mice born of fathers who are habitually exposed to nicotine inherit enhanced chemical tolerance and drug clearance abilities. These findings offer a powerful framework for exploring how information about a father's environmental exposure history is passed down to offspring. "Children born of fathers who have been exposed to nicotine are programmed to be not only more resistant to nicotine toxicity, but to other chemicals as well," said Dr. Rando, professor of biochemistry & molecular pharmacology. "If a similar phenomenon occurs in humans, this raises many important questions. For example, if your father smoked does that mean chemotherapy might be less effective for you? Are you more or less likely to smoke? It's important to understand what information is specifically being passed down from father to offspring and how that impacts us." Studies over the past decade in the field of epigenetics - the study of inheritable traits that are carried outside the genome - have provided unexpected support to the notion that the environmental conditions experienced by a parent can affect disease risk and other features of future generations. In mammals, many of these studies have focused on interactions between the male parent and the offspring - paternal effects - as these are in many ways easier to investigate than maternal effects. Specifically, a number of studies have linked paternal diet to metabolic changes in offspring, while others link paternal stress to anxiety-like behaviors in the next generation. Despite the growing number of these studies, only a small number of paternal exposures have been explored rigorously in the lab. In addition, it has remained unclear in these studies whether the offspring response is specific for the paternal exposure, or whether it is a more generic response to a father's overall quality of life. To address this question, Rando and colleagues set out to determine how precise the response is for the environment experienced by the male parent, by looking at a single molecular interaction. Nicotine is a commonly used drug in humans, and acts by binding to a specific molecular receptor. Providing male mice with access to nicotine, researchers sought to learn whether their offspring were more or less sensitive to nicotine, and whether the offspring response was specific to nicotine or extended to other molecules. What researchers found is that the offspring of nicotine-exposed fathers, compared to the offspring of fathers that were never exposed to nicotine, were protected from toxic levels of nicotine. Researchers then tested whether this resistance was specific for nicotine by treating both sets of offspring with cocaine, which acts via a wholly distinct molecular pathway than nicotine. Surprisingly, the children of nicotine-exposed fathers were also protected from cocaine. This multi-toxin resistance is likely a result of enhanced drug metabolism in the liver, and corresponds to an increase in expression levels of genes involved in drug metabolism. These genes were also packaged in a more open and accessible configuration in the liver cells, allowing for increased expression. "This demonstrates that 'dad' paints with very broad brush strokes. Fathers exposed to nicotine do not specifically program changes in nicotine receptors in their children, as these children are broadly resistant to multiple toxins," said Rando. To determine if multiple, distinct molecules are capable of affecting drug resistance in the next generation, Rando and colleagues treated male mice with another bioactive compound, mecamylamine, which blocks nicotine receptors and is sometimes used to help people stop smoking. Surprisingly, offspring of these mice exhibited the same chemical resistance as those exposed to nicotine. "These findings raise key questions about what drugs or molecules are sufficient to affect children of exposed fathers," said Rando. "What distinguishes nicotine and mecamylamine from the countless small molecules present in our food and environment?" The next step for Rando and colleagues is to determine how many channels of information are being passed down from parent to offspring. "We now know that this information is relatively nonspecific," he said. "But is dad only telling us, on a scale of 1 to 10, that his life was good or not, or is he telling us four or five things broadly about the amount of food, level of stress and degree of chemical exposure?" Given the prevalence of smoking in humans, Rando notes that "there are obvious reasons to be interested in whether this type of effect also happens in human beings, but given the differences between mice and humans in their metabolism of nicotine, it will need to be tested rigorously in future studies of human populations." The University of Massachusetts Medical School (UMMS), one of five campuses of the University system, is comprised of the School of Medicine, the Graduate School of Biomedical Sciences, the Graduate School of Nursing, a thriving research enterprise and an innovative public service initiative, Commonwealth Medicine. Its mission is to advance the health of the people of the Commonwealth through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. In doing so, it has built a reputation as a world-class research institution and as a leader in primary care education. The Medical School attracts more than $266 million annually in research funding, placing it among the top 50 medical schools in the nation. In 2006, UMMS's Craig C. Mello, PhD, Howard Hughes Medical Institute Investigator and the Blais University Chair in Molecular Medicine, was awarded the Nobel Prize in Physiology or Medicine, along with colleague Andrew Z. Fire, PhD, of Stanford University, for their discoveries related to RNA interference (RNAi). The 2013 opening of the Albert Sherman Center ushered in a new era of biomedical research and education on campus. Designed to maximize collaboration across fields, the Sherman Center is home to scientists pursuing novel research in emerging scientific fields with the goal of translating new discoveries into innovative therapies for human diseases.
News Article | March 1, 2017
RYE, N.Y.--(BUSINESS WIRE)--GAMCO Investors, Inc., (NYSE: GBL) announced the appointment of Robert D. Leininger CFA, and Justin L. Bergner CFA to the investment team of the Gabelli Dividend Growth Fund (the “Fund”) effective March 1, 2017. Messrs. Leininger and Bergner, join Barbara G. Marcin CFA, who has been the portfolio manager of the Fund since its launch on August 26, 1999. Prior to joining Gabelli, Barbara Marcin was head of Value Investments at Citibank, where she worked from 1993 to 1999. In this capacity, Barbara headed up the team responsible for managing $1.2 billion in mutual funds and separate accounts, and was a member of the US Investment Policy Committee. She previously worked at Fiduciary Trust Company International and at E.F. Hutton & Company. A Chartered Financial Analyst, Ms. Marcin received her Masters of Business Administration from Harvard University’s Graduate School of Business and her undergraduate degree from the University of Virginia, where she graduated with Distinction, as an Echols Scholar. Commenting on the appointments, Mr. Mario J. Gabelli said, “We are delighted to have Bob and Justin join the team. They will make a value added addition to our team to find investments that meet the objectives of (y)our Fund.” Bob Leininger joined Gabelli in 1993 as a security analyst covering the beverage industry after earning his MBA from the Wharton School at the University of Pennsylvania. Bob rejoined Gabelli in 2010. He holds the Chartered Financial Analyst designation and is a member of the Financial Analyst Society of Philadelphia. Bob is a magna cum laude graduate of Amherst College with a degree in Economics. Since September 27, 2010, Bob has been a Portfolio Manager of the Gabelli Dividend and Income Trust. (NYSE:GDV) and since June 1, 2015 a Portfolio Manager of the Gabelli Equity Trust (NYSE:GAB). Justin Bergner is currently a Vice President at Gabelli & Company and a portfolio manager for Gabelli Funds LLC, the Adviser. Justin rejoined Gabelli & Company in 2013 as a research analyst covering Diversified Industrials, Home Improvement, and Transport companies. He began his investment career at Gabelli & Company in 2005 as a metals and mining analyst, and subsequently spent five years at Axiom International Investors as a senior analyst focused on industrial and healthcare stocks. Prior to business school, Mr. Bergner worked in management consulting at both Bain & Company and Dean & Company. A Chartered Financial Analyst, Mr. Bergner graduated cum laude from Yale University with a B.A. in Economics & Mathematics and received an M.B.A. in Finance and Accounting from the Wharton School at the University of Pennsylvania. The Gabelli Dividend Growth Fund Inc. is a diversified, open-end management investment company whose primary investment objective is long term growth of capital. Current income is a secondary objective of the Fund. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (NYSE:GBL), which through its subsidiaries, manages assets of private advisory accounts (GAMCO Asset Management Inc.), mutual funds and closed-end funds (Gabelli Funds, LLC), and is known for its Private Market Value with a Catalyst™ style of investment. As of December 31, 2016, GAMCO Investors, Inc. had $39.7 billion in assets under management. Investors should carefully consider the investment objectives, risks, charges and expenses of the Fund before investing. The prospectus, which contains more complete information about this and other matters, should be read carefully before investing. To obtain a prospectus, please call 800 GABELLI or visit www.gabelli.com The Gabelli Mutual Funds are distributed by G.distributors, LLC. a registered broker dealer and member of FINRA
News Article | February 15, 2017
The National Association of Professional Women (NAPW) honors Lynnette Duenas as a 2016-2017 inductee into its VIP Woman of the Year Circle. She is recognized with this prestigious distinction for leadership in business. NAPW is the nation’s leading networking organization exclusively for professional women, boasting more than 850,000 members, a thriving eChapter and over 200 operating Local Chapters. “I’m pleased to welcome Lynnette into this exceptional group of professional women,” said NAPW President Star Jones. “Her knowledge and experience in her industry are valuable assets to her company and community.” Self-motivated and results driven to succeed, Lynnette Duenas is a seasoned professional who has constantly set her goals to keep pace with her highest aspirations for personal excellence. Throughout her career, she has exhibited exemplary teamwork, expertise, integrity and dedication. Ms. Duenas’ professional title is Line Manager at Vanguard. Her skills and areas of expertise include management and financial operations. She is currently involved with the National Society of Hispanic MBAs and is extremely passionate about charitable organizations such as Sponsor a Child through Children’s International and Management Leadership for Tomorrow. She received her MBA from Cornell University - Johnson Graduate School of Management. The unwavering dedication demonstrated by Ms. Duenas fully utilizes the aspirations for success that have earned her this recognition from the National Association of Professional Women, honoring her as an inspiration and a leader in her industry. About NAPW NAPW’s mission is to provide an exclusive, highly advanced networking forum to successful women executives, professionals and entrepreneurs where they can aspire, connect and achieve. Through innovative resources, unique tools and progressive benefits, professional women interact, exchange ideas, advance their knowledge and empower each other.
News Article | February 28, 2017
SYRACUSE, NY, February 28, 2017-- John Mathiason is a celebrated Marquis Who's Who biographee. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Marquis Who's Who, the world's premier publisher of biographical profiles, is proud to name John Mathiason a Lifetime Achiever. An accomplished listee, John Mathiason celebrates many years' experience in his professional network, and has been noted for achievements, leadership qualities, and the credentials and successes he has accrued in his field.Dr. Mathiason is currently an adjunct professor at the Cornell Institute for Public Affairs of Cornell University.In light of Dr. Mathiason's fervor for education, he was awarded the Distinguished Adjunct Professor Award from the Graduate School of Public Administration at New York University. He has also earned inclusion in Marquis Who's Who in the World, Who's Who in the East, Who's Who in American Politics, and Who's Who in America.In recognition of outstanding contributions to his profession and the Marquis Who's Who community, John Mathiason has been featured on the Marquis Who's Who Lifetime Achievers website. Please visit http://whoswholifetimeachievers.com/2017/01/04/john-mathiason/ to view this distinguished honor.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com
News Article | March 2, 2017
Southern Illinois University Edwardsville Chancellor Randy Pembrook has named Denise Cobb, PhD, as provost and vice chancellor for academic affairs. The selection is pending Board of Trustees approval. Cobb served as the interim provost since October 2015. Prior to that appointment, she was assistant provost for academic innovation and effectiveness, and then associate provost for academic affairs since June 2012. “The search committee and Chancellor Pembrook have made the absolute right decision for the SIUE campus community, and I want to congratulate Dr. Cobb on being recommended to the SIU board of trustees for the provost’s position,” said SIU President Randy Dunn. “Denise has been a great steward during her interim service and this appointment will allow her to continue the positive steps she already has underway for the benefit of our students, faculty and academic staff. I’ve enjoyed working with her this past year and look forward to doing so in the future.” “All of us, who have had a chance to interact with Dr. Cobb as part of the interview process or through interactions during her period as interim provost, recognize her many positive qualities such as institutional knowledge, decisiveness, building positive relationships with individuals at SIUE and in the community, thorough knowledge of our budget processes, and her dedication to SIUE,” Pembrook said. “I know Dr. Cobb will hit the ground running and will continue to offer great leadership in the academic arena.” “I am grateful for the opportunity to continue serving this University and community,” Cobb said. “I am humbled to be a part of this vibrant campus and to have this opportunity to lead and work collaboratively with faculty, staff and students. I sincerely appreciate the work of the search committee and everyone who participated in this process. I want to thank Chancellor Pembrook and the SIUE community for their support.” “Together, we will build on our excellent academic programs that meet the needs of current and future students, while serving the needs of the region, state and world. I am excited to support the good work that we have already accomplished, and I will encourage the innovative possibilities that will drive our future. It is a great honor and responsibility to help nurture a campus climate that reflects our commitment to excellence, diversity, inclusion, and equity.” In the Office of the Provost, Cobb’s responsibilities and achievements have included: “During the evaluation of candidates, Dr. Cobb’s commitment to shared governance, and her willingness to mediate between those with differing opinions, soon emerged as a common thread among those participating in the feedback process,” said Anthony Cheeseboro, PhD, search committee chair and associate professor of historical studies in the SIUE College of Arts and Sciences. “It is clear that the faculty and staff at SIUE see Dr. Cobb as approachable, yet highly capable, and uniquely knowledgeable about the issues important to this University. Those factors, along with her commitment to diversity, made her an outstanding choice among a very strong field of candidates.” “As a first generation college graduate, I believe in the possibilities and power of higher education, and an SIUE education, in particular,” Cobb said. “I am confident in our ability to work collaboratively to achieve our goals, positively influence the region and ensure the success of our students.” Cobb joined the SIUE Department of Sociology and Criminal Justice Studies in 2003 as an assistant professor in sociology and was promoted to professor in 2015. As a faculty member committed to interdisciplinary scholarship, she has co-authored and co-presented with colleagues from a wide variety of disciplines on such topics as capstone experiences for college students and LGBT issues in criminal justice education. She has been integrally involved in numerous externally funded research projects with the SIUE Graduate School and is dedicated to broadening participation and success of under-represented student and faculty populations in STEM (science, technology, engineering and math) graduate programs. An Arkansas native, Cobb earned a bachelor’s in sociology from the University of Arkansas at Little Rock in 1993 where she was a Donaghey Scholar. She earned a master’s in 1995 from the University of Central Arkansas and a doctorate from Tulane University in 2003. Southern Illinois University Edwardsville provides students with a high quality, affordable education that prepares them for successful careers and lives of purpose. Built on the foundation of a broad-based liberal education, and enhanced by hands-on research and real-world experiences, the academic preparation SIUE students receive equips them to thrive in the global marketplace and make our communities better places to live. Situated on 2,660 acres of beautiful woodland atop the bluffs overlooking the natural beauty of the Mississippi River’s rich bottomland and only a short drive from downtown St. Louis, the SIUE campus is home to a diverse student body of more than 14,000.
News Article | February 28, 2017
WELLESLEY, Mass., Feb. 28, 2017 /PRNewswire-USNewswire/ -- The 2017 Financial Times Global Full-Time MBA Ranking has named Babson College's F.W. Olin Graduate School of Business the No. 3 graduate program for Entrepreneurship. Stanford and MIT are ranked above Babson. In addition,...